Sawai Announces Listing of Five Generic Drugs with 11 Strengths

Jun. 16. 2022

Osaka, Japan – June 16, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with 11 strengths in the NHI (National Health Insurance) drug price list. Sawai’s product line now includes 329 compounds with 809 strengths.

The list of approved products

1. Febuxostat Tablets, OD Tablets

Generic name Febuxostat
Strengths Tablets: 10mg, 20mg, 40mg
OD Tablets: 10mg, 20mg
Brand products Feburic® Tablets 10mg, 20mg, 40mg

2. Aripiprazole Tablets, Oral Solution

Generic name Aripiprazole
Strengths Tablets: 1mg
Oral Solution: 1mg
Brand products ABILIFY® tablets 1mg, ABILIFY®oral solution 0.1%

3. Dasatinib Tablets

Generic name Dasatinib Hydrate
Strengths Tablets: 20mg, 50mg
Brand products SPRYCEL® Tablets 20mg, 50mg

4. Azacitidine for Injection

Generic name Azacitidine
Strengths Injection: 100mg
Brand products Vidaza® for Injection 100mg

5. Teriparatide Injection

Generic name Teriparatide Acetate
Strengths Injection: 56.5μ
Brand products Teribone® Injection 56.5μg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.